LOXL2 and cancer: Additionally, it should be considered that small-molecular-weight LOXL2 inhibitors are designed to block the catalytic activity of the enzyme, and we know that the classical oxidase activity is not required for many of the intracellular functions of LOXL2 in cancer, such as the induction of EMT.